CA2466502A1 - Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles - Google Patents

Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles Download PDF

Info

Publication number
CA2466502A1
CA2466502A1 CA002466502A CA2466502A CA2466502A1 CA 2466502 A1 CA2466502 A1 CA 2466502A1 CA 002466502 A CA002466502 A CA 002466502A CA 2466502 A CA2466502 A CA 2466502A CA 2466502 A1 CA2466502 A1 CA 2466502A1
Authority
CA
Canada
Prior art keywords
panel
data set
constituents
profile data
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002466502A
Other languages
English (en)
French (fr)
Inventor
Michael Bevilacqua
John C. Cheronis
Victor Tryon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27502635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2466502(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2466502A1 publication Critical patent/CA2466502A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G01N33/57515—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002466502A 2001-11-09 2002-11-08 Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles Abandoned CA2466502A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US34821301P 2001-11-09 2001-11-09
US60/348,213 2001-11-09
US34088101P 2001-12-07 2001-12-07
US60/340,881 2001-12-07
US36963302P 2002-04-03 2002-04-03
US60/369,633 2002-04-03
US37699702P 2002-04-30 2002-04-30
US60/376,997 2002-04-30
PCT/US2002/036084 WO2003040404A1 (en) 2001-11-09 2002-11-08 Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles

Publications (1)

Publication Number Publication Date
CA2466502A1 true CA2466502A1 (en) 2003-05-15

Family

ID=27502635

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002466502A Abandoned CA2466502A1 (en) 2001-11-09 2002-11-08 Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles

Country Status (7)

Country Link
US (4) US6964850B2 (enExample)
EP (1) EP1451340B1 (enExample)
JP (2) JP5236856B2 (enExample)
KR (1) KR20040064275A (enExample)
CN (2) CN1612936A (enExample)
CA (1) CA2466502A1 (enExample)
WO (1) WO2003040404A1 (enExample)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
CA2466502A1 (en) 2001-11-09 2003-05-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
JP4323957B2 (ja) * 2002-01-22 2009-09-02 バイオマテラ インコーポレイテッド 生物分解性ポリマーの乾燥方法
AU2003299503A1 (en) * 2002-05-16 2004-06-15 Vanderbilt University Method for predicting autoimmune diseases
US20040157242A1 (en) * 2002-11-12 2004-08-12 Becton, Dickinson And Company Diagnosis of sepsis or SIRS using biomarker profiles
CN1829730A (zh) 2002-11-12 2006-09-06 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
CA2505902A1 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
EP1570080A4 (en) * 2002-11-15 2006-03-01 Genomic Health Inc GENE EXPRESSION PROFILING OF EGFR-POSITIVE CANCER DISEASE
BR0317612A (pt) * 2002-12-19 2005-12-06 Source Precision Medicine Inc Identificação, monitoração e tratamento de doença infecciosa e caracterização de condições inflamatórias relacionadas com doença infecciosa empregando perfis de expressão de gene
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2515096A1 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US20080014579A1 (en) * 2003-02-11 2008-01-17 Affymetrix, Inc. Gene expression profiling in colon cancers
DE602004017426D1 (de) * 2003-02-20 2008-12-11 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2004111273A2 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
JP4680898B2 (ja) * 2003-06-24 2011-05-11 ジェノミック ヘルス， インコーポレイテッド 癌再発の可能性の予測
CA2531281A1 (en) * 2003-07-03 2005-01-27 Gentron, Llc Methods and systems for diagnosis of non-central nervous system (cns) diseases in cns samples
EP3330875B1 (en) 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
CA2534661A1 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
JP2007509613A (ja) * 2003-10-16 2007-04-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現プロファイリングのためのｑＲＴ−ＰＣＲアッセイシステム
US20050196782A1 (en) * 2003-12-23 2005-09-08 Kiefer Michael C. Universal amplification of fragmented RNA
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US7645575B2 (en) 2004-09-08 2010-01-12 Xdx, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
CA3061785A1 (en) 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP1815014B1 (en) * 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
US20060157647A1 (en) * 2005-01-18 2006-07-20 Becton, Dickinson And Company Multidimensional liquid chromatography/spectrometry
US7767395B2 (en) 2005-04-15 2010-08-03 Becton, Dickinson And Company Diagnosis of sepsis
EP1904657B1 (en) 2005-06-08 2011-05-25 Hitachi Chemical Research Center, Inc. METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
JP5024583B2 (ja) * 2005-09-14 2012-09-12 ソニー株式会社 情報処理装置および情報処理方法、情報処理システム、プログラム、並びに、記録媒体
DK1974058T3 (da) * 2006-01-11 2014-09-01 Genomic Health Inc Genekspressionsmarkører til prognosticering af kolorektal cancer
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
JP5027209B2 (ja) 2006-04-07 2012-09-19 日立化成工業株式会社 クローン病患者の末梢血白血球におけるＴ細胞受容体介在性腫瘍壊死因子スーパーファミリー及びケモカインのｍＲＮＡ発現の増強
WO2009070442A2 (en) 2007-11-14 2009-06-04 Hitachi Chemical Co. Ltd. Fc receptor-mediated tumor necrosis factor superfamily mrna expression in peripheral blood leukocytes
CN101438304A (zh) * 2006-05-10 2009-05-20 皇家飞利浦电子股份有限公司 为分类学习变换测量数据
US20080227655A1 (en) * 2006-05-16 2008-09-18 Michael Bevilacqua Assessment of effect of an agent on a human biological condition using rodent gene expression panels
WO2008016111A1 (fr) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Procédé permettant d'évaluer un cancer du poumon, dispositif d'évaluation d'un cancer du poumon, procédé d'évaluation d'un cancer du poumon, système d'évaluation d'un cancer du poumon, programme d'évaluation d'
US7993832B2 (en) 2006-08-14 2011-08-09 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
CN101568838A (zh) * 2006-12-21 2009-10-28 味之素株式会社 评估癌症状态的方法、癌症评估装置、癌症评估方法、癌症评估系统、癌症评估程序和记录介质
WO2008075662A1 (ja) 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体
JP5746811B2 (ja) * 2006-12-21 2015-07-08 味の素株式会社 大腸癌の評価方法、ならびに大腸癌評価装置、大腸癌評価方法、大腸癌評価システム、大腸癌評価プログラムおよび記録媒体
US20090117562A1 (en) 2007-04-09 2009-05-07 Valerie Wailin Hu Method and kit for diagnosing Autism using gene expression profiling
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9360489B2 (en) * 2007-06-11 2016-06-07 Sutter Bay Hospitals Method and kit for dynamic gene expression monitoring
US8068994B2 (en) * 2007-07-27 2011-11-29 Wayne State University Method for analyzing biological networks
KR101711860B1 (ko) * 2008-01-25 2017-03-03 베르그 엘엘씨 발암성, 종양 진행 및 치료 효능을 평가하는 분석 시스템
CN104407158B (zh) * 2008-02-06 2019-03-29 味之素株式会社 胃癌的评价方法、以及胃癌评价装置、胃癌评价方法、胃癌评价系统、胃癌评价程序和记录介质
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
US7776522B2 (en) * 2008-04-24 2010-08-17 Becton, Dickinson And Company Methods for diagnosing oncogenic human papillomavirus (HPV)
EP2294216A4 (en) 2008-05-14 2011-11-23 Dermtech Int DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN104316701B (zh) * 2008-06-20 2018-05-15 味之素株式会社 女性生殖器癌症的评价方法
KR101821551B1 (ko) 2008-06-20 2018-01-25 아지노모토 가부시키가이샤 전립선 질환의 평가 방법
CA2734521A1 (en) * 2008-08-28 2010-03-04 Dermtech International Determining age ranges of skin samples
US8236503B2 (en) 2008-11-07 2012-08-07 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8691510B2 (en) 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
US8685898B2 (en) 2009-01-15 2014-04-01 Imdaptive, Inc. Adaptive immunity profiling and methods for generation of monoclonal antibodies
US10179936B2 (en) * 2009-05-01 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
CA2765949C (en) 2009-06-25 2016-03-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
WO2011156734A2 (en) * 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Method of characterizing vascular diseases
WO2011156763A1 (en) 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Methods for characterizing kidney function
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
WO2012021714A2 (en) * 2010-08-12 2012-02-16 William Marsh Rice University Biomarker signatures for wellness testing
WO2012070056A2 (en) 2010-11-23 2012-05-31 Krisani Biosciences (P) Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
WO2012109435A1 (en) * 2011-02-12 2012-08-16 Siemens Healthcare Diagnostics Inc Environment and method for analysis of genetic sequence data
WO2012170037A1 (en) 2011-06-10 2012-12-13 Hitachi Chemical Co., Ltd. Vesicle capturing devices and methods for using same
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
WO2013059725A1 (en) 2011-10-21 2013-04-25 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
ES2778057T3 (es) 2011-11-14 2020-08-07 Aushon Biosystems Inc Sistemas y métodos para mejorar la consistencia del rendimiento de un ensayo
EP3388535B1 (en) 2011-12-09 2021-03-24 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
WO2013116144A1 (en) 2012-01-31 2013-08-08 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
MX354329B (es) 2012-05-08 2018-02-27 Adaptive Biotechnologies Corp Composiciones y metodos para medir y calibrar el error de amplificacion en reacciones de pcr multiple.
KR20150014986A (ko) 2012-05-22 2015-02-09 버그 엘엘씨 약물-유도 독성 마커의 확인을 위한 인테로거토리 세포 기반 분석방법
FR2993282B1 (fr) * 2012-07-13 2017-11-10 Expanscience Lab Procede d'identification de marqueurs moleculaires de la peau d'enfant
EP2895861A4 (en) 2012-09-12 2016-06-22 Berg Llc USE OF MARKERS FOR THE IDENTIFICATION OF CARDIOTOXIC AGENTS
RU2015113523A (ru) * 2012-09-14 2016-11-10 Лайф Текнолоджиз Корпорейшн Способы и системы для средств планирования экспериментов цифровой пцр
ES2749118T3 (es) 2012-10-01 2020-03-19 Adaptive Biotechnologies Corp Evaluación de la inmunocompetencia por la diversidad de los receptores de inmunidad adaptativa y caracterización de la clonalidad
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
JP6671276B2 (ja) 2013-03-27 2020-03-25 セダーズ−シナイ メディカル センター Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
DE212013000295U1 (de) 2013-05-06 2016-02-02 Hitachi Chemical Co. America, Ltd. Vorrichtungen zum Einfangen von Zielmolekülen
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
JP6703479B2 (ja) * 2013-12-16 2020-06-03 フィリップ モリス プロダクツ エス アー 個人の喫煙ステータスを予測するためのシステムおよび方法
EP3094747B1 (en) * 2014-01-16 2018-11-07 Illumina, Inc. Gene expression panel for prognosis of prostate cancer recurrence
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
AU2015289434A1 (en) * 2014-07-18 2017-02-02 Genova Diagnostics, Inc. Use of an evidence-based, translational algorithm to, inter alia, assess biomarkers
ES2784343T3 (es) 2014-10-29 2020-09-24 Adaptive Biotechnologies Corp Detección simultánea altamente multiplexada de ácidos nucleicos que codifican heterodímeros de receptores inmunes adaptativos emparejados de muchas muestras
US10266895B2 (en) 2014-11-05 2019-04-23 Hitachi Chemical Company Ltd. Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
JP6631852B2 (ja) 2014-11-12 2020-01-15 日立化成株式会社 臓器障害を診断するための方法および装置
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2015353581A1 (en) 2014-11-25 2017-06-15 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
US11047008B2 (en) 2015-02-24 2021-06-29 Adaptive Biotechnologies Corporation Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
JP6232689B2 (ja) 2015-06-25 2017-11-22 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
WO2017009770A1 (en) * 2015-07-13 2017-01-19 Koninklijke Philips N.V. Tracking infections in hospital environments
WO2017040520A1 (en) 2015-08-31 2017-03-09 Hitachi Chemical Co., Ltd. Molecular methods for assessing urothelial disease
CN105279397B (zh) * 2015-10-26 2017-12-19 华东交通大学 一种识别蛋白质相互作用网络中关键蛋白质的方法
KR101795662B1 (ko) * 2015-11-19 2017-11-13 연세대학교 산학협력단 대사 이상 질환 진단 장치 및 그 방법
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
US11180539B2 (en) 2016-03-29 2021-11-23 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
EP3438282A4 (en) 2016-03-29 2020-05-06 Advanced Telecommunications Research Institute International METHOD FOR SCREENING CANDIDATE SUBSTANCES FOR AN ACTIVE COMPONENT TO PREVENT OR TREAT AT LEAST ONE SELECTED DISEASE IN THE KIDNEY HYPOFUNCTION GROUP, CHRONIC KIDNEY DISEASE AND KIDNEY DEFICIENCY
US10607720B2 (en) 2016-05-11 2020-03-31 International Business Machines Corporation Associating gene expression data with a disease name
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
CN106709267A (zh) * 2017-01-25 2017-05-24 武汉贝纳科技服务有限公司 数据获取方法及装置
CN107058521B (zh) * 2017-03-17 2019-12-27 中国科学院北京基因组研究所 一种检测人体免疫状态的检测系统
JPWO2019066044A1 (ja) 2017-09-29 2020-12-10 ファーマバイオ株式会社 標準化発現量を利用した再生医療製品等の品質管理の手法
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
EP3752645A4 (en) 2018-02-14 2022-04-13 Dermtech, Inc. NEW GENE CLASSIFIERS AND THEIR USE IN NON-MELANOMA SKIN CANCER
EP3762506A4 (en) * 2018-02-21 2022-03-23 Edifice Health, Inc. METHOD OF MEASURING AGING DUE TO CHRONIC SYSTEMIC INFLAMMATION
CA3093053A1 (en) * 2018-03-13 2019-09-19 Creatv Microtech, Inc. Methods for monitoring treatment response and disease progression in subjects using circulating cells
WO2019193241A1 (en) * 2018-04-03 2019-10-10 Nokia Technologies Oy Use of band combination index for definition of carrier aggregation configurations
KR102170726B1 (ko) * 2018-10-04 2020-10-27 사회복지법인 삼성생명공익재단 바이오마커의 선별 방법 및 이를 이용한 암의 진단을 위한 정보제공방법
JP2022524641A (ja) 2019-03-26 2022-05-09 ダームテック，インク． 皮膚癌における新規な遺伝子分類子とその使用
JP7180676B2 (ja) * 2019-03-26 2022-11-30 Ｊｆｅスチール株式会社 プロセス状態監視装置及びプロセス状態監視方法
WO2021119499A1 (en) * 2019-12-13 2021-06-17 Janssen Biotech, Inc. Materials and methods for inflammatory molecular markers
US20250230502A1 (en) * 2022-03-30 2025-07-17 National Cancer Center Ifi16 mutant gene as a marker for risk prediction, diagnosis or prognosis of chronic liver disease and uses thereof
CN118298911B (zh) * 2024-04-12 2024-11-22 中山大学孙逸仙纪念医院 一种多部位慢性疼痛潜在治疗靶点确定系统

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5580722A (en) 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US5569601A (en) * 1990-12-07 1996-10-29 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Human dopamine receptor and its uses
US6114114A (en) 1992-07-17 2000-09-05 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
EP0680517B2 (en) 1993-01-21 2005-01-19 President And Fellows Of Harvard College Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
AU678234B2 (en) 1993-04-21 1997-05-22 University Of Edinburgh, The Expression of heterologous genes according to a targeted expression profile
US6309823B1 (en) * 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
US7625697B2 (en) 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5506145A (en) * 1994-12-02 1996-04-09 Bull; Brian S. Determination of an individual's inflammation index from whole blood fibrinogen and hematocrit or hemoglobin measurements
US5696133A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5968770A (en) * 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US5866330A (en) 1995-09-12 1999-02-02 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US5922184A (en) 1997-07-21 1999-07-13 Bio-Rad Laboratories, Inc. Computer-directed detection of paraproteins
FR2775984B1 (fr) 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
ATE335843T1 (de) 1996-05-02 2006-09-15 Applera Corp Quantifizierung von rna-transkripten mittels genomischer dna als internen standard der amplifizierungsreaktion
US5955269A (en) 1996-06-20 1999-09-21 Rutgers, The State University Of New Jersey Methods of screening foods for nutraceuticals
US6146828A (en) 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
AU722819B2 (en) 1996-12-06 2000-08-10 Urocor, Inc. Diagnosis of disease state using mRNA profiles
JPH10261029A (ja) 1996-12-16 1998-09-29 Nissho Corp アルツハイマー病生涯罹病性の予測システム
US5968784A (en) 1997-01-15 1999-10-19 Chugai Pharmaceutical Co., Ltd. Method for analyzing quantitative expression of genes
US6165709A (en) 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
AU9217198A (en) 1997-09-03 1999-03-22 Oncormed Method for predicting prognosis and treatment response for genetically based abnormalities
ATE291097T1 (de) 1997-10-31 2005-04-15 Affymetrix Inc A Delaware Corp Expressionsprofile in adulten und fötalen organen
JP3784162B2 (ja) 1998-01-14 2006-06-07 株式会社日立製作所 Ｄｎａ断片分析法
ES2317380T3 (es) 1998-02-25 2009-04-16 The United States Government As Represented By The Department Of Health And Human Services Metodo y aparato para preparar especimenes tisulares para un analisis paralelo.
CA2325343A1 (en) 1998-04-23 1999-10-28 Genentech, Inc. Quantitative analysis of gene expression
CA2326827A1 (en) 1998-05-05 1999-11-11 Gene Logic, Inc. A process to study changes in gene expression in t lymphocytes
US6232065B1 (en) 1998-05-06 2001-05-15 Case Western Reserve University Analysis of gene family expression
US6324479B1 (en) 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
CN1309722A (zh) 1998-05-12 2001-08-22 罗斯塔英法美蒂克斯公司 定量分析基因表达的方法、系统及设备
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6132969A (en) 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
US6670194B1 (en) 1998-08-25 2003-12-30 University Of Washington Rapid quantitative analysis of proteins or protein function in complex mixtures
US6185561B1 (en) 1998-09-17 2001-02-06 Affymetrix, Inc. Method and apparatus for providing and expression data mining database
US6245517B1 (en) 1998-09-29 2001-06-12 The United States Of America As Represented By The Department Of Health And Human Services Ratio-based decisions and the quantitative analysis of cDNA micro-array images
AU1115200A (en) 1998-10-13 2000-05-01 Clontech Laboratories, Inc. Nucleic acid arrays
US6203987B1 (en) 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
CA2316802A1 (en) 1998-11-05 2000-05-18 Ortho-Mcneil Pharmaceutical, Inc. Method for generating gene expression profiles
US6222093B1 (en) 1998-12-28 2001-04-24 Rosetta Inpharmatics, Inc. Methods for determining therapeutic index from gene expression profiles
AU3326000A (en) * 1999-03-26 2000-10-16 George Hosokawa Means of early examination of malignant tumor
AU4698600A (en) 1999-05-05 2000-11-17 Ut-Battelle, Llc Method and apparatus for combinatorial chemistry
EP1190366B1 (en) 1999-05-25 2005-10-26 Aventis Pharmaceuticals Inc. Mathematical analysis for the estimation of changes in the level of gene expression
WO2001025473A1 (en) * 1999-06-28 2001-04-12 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles
EP1330539A2 (en) 1999-08-09 2003-07-30 Affymetrix, Inc. Methods of gene expression monitoring
AU782102B2 (en) 1999-08-12 2005-07-07 Wisconsin Alumni Research Foundation Identification of genetic markers of biological age and metabolism
WO2001020998A1 (en) 1999-09-24 2001-03-29 Linden Technologies, Inc. Drug discovery using gene expression profiling
US6505125B1 (en) 1999-09-28 2003-01-07 Affymetrix, Inc. Methods and computer software products for multiple probe gene expression analysis
AU1179001A (en) 1999-10-13 2001-04-23 Plant Research International B.V. Method for detecting differences in gene expression between wild type plants andnewly developed plants
US6607885B1 (en) 1999-10-15 2003-08-19 E. I. Du Pont De Nemours And Company Method for high-density microarray medicated gene expression profiling
AU784861B2 (en) 1999-10-21 2006-07-06 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
JP2003533970A (ja) 1999-10-26 2003-11-18 ディジタル・ジーン・テクノロジーズ・インコーポレーテッド 神経遮断薬による遺伝子発現の制御
WO2001032928A2 (en) 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
WO2001075159A2 (en) 2000-03-31 2001-10-11 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
US7384736B2 (en) * 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
CA2466502A1 (en) 2001-11-09 2003-05-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles

Also Published As

Publication number Publication date
EP1451340B1 (en) 2014-01-08
US8055452B2 (en) 2011-11-08
US6964850B2 (en) 2005-11-15
US20050287576A1 (en) 2005-12-29
US8718946B2 (en) 2014-05-06
CN102402650A (zh) 2012-04-04
CN1612936A (zh) 2005-05-04
EP1451340A1 (en) 2004-09-01
JP5236856B2 (ja) 2013-07-17
KR20040064275A (ko) 2004-07-16
JP2011067214A (ja) 2011-04-07
US20100086935A1 (en) 2010-04-08
US20030219771A1 (en) 2003-11-27
JP2005508505A (ja) 2005-03-31
EP1451340A4 (en) 2007-04-11
US20120077199A1 (en) 2012-03-29
WO2003040404A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
US6960439B2 (en) Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6964850B2 (en) Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20180060481A1 (en) Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
EP1198585B1 (en) Method for characterizing a biological condition using calibrated gene expression profiles
US20030229455A1 (en) Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US7935482B2 (en) Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
JP2005508505A5 (enExample)
AU2003303238B2 (en) Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
US20060115826A1 (en) Gene expression profiling for identification monitoring and treatment of multiple sclerosis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20180510